Lenaic Nathanael Teyssedou, Principal Accounting Officer of Addex Therapeutics Ltd. (NASDAQ:ADXN), filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.
Addex Therapeutics Ltd. (NASDAQ:ADXN) Chief Medical Officer and Director Roger Mills filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.
Director Raymond George Hill of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share.
Director Vincent Michael Lawton of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share and an expiration date of October 11, 2036.
Director Brett Huckelbridge of Global Water Resources, Inc. filed a Form 4 on November 13, 2026, reporting the acquisition of 1,349 shares of common stock on November 10, 2026.
Global Water Resources, Inc. director Richard M Alexander filed a Form 4 on November 13, 2026, reporting transactions in the company's common stock dated November 10, 2026.
Director Andrew M. Cohn of Global Water Resources, Inc. filed a Form 4 on November 13, 2026, disclosing the acquisition of 1,029 shares of common stock on November 10, 2026.
Director Christa Steele of Global Water Resources, Inc. filed a Form 4 on November 13, 2026, reporting the acquisition of 1,493 shares of common stock on November 10, 2026.
A Form 4 filed on November 13, 2026 with the U.S. Securities and Exchange Commission reports that David Rousseau, a director of Global Water Resources, Inc., acquired 1,489 shares of common stock on November 10, 2026.
Director Jonathan L. Levine filed a Form 4 with the SEC on November 13, 2026, disclosing the acquisition of 1,029 shares of common stock in Global Water Resources, Inc. (NASDAQ:GWRS) on November 10, 2026.